Who are Cannabidiol 400's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): THC/CBD, medical cannabis, Single-dose of cannabis oil, Dronabinol in Oral Dosage Form, Dronabinol Capsules, CimetrA-2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cannabidiol-400.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cannabidiol 400 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cannabidiol 400 (Cannabidiol 400) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cannabinoid receptor agonist. Area: Neurology.

phase 2 cannabinoid receptor agonist CB1 and CB2 receptors Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Cannabidiol 400 (Cannabidiol 400) — Hurd,Yasmin, Ph.D.. Cannabidiol 400 acts as a cannabinoid receptor agonist, modulating the endocannabinoid system to exert therapeutic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Cannabidiol 400 TARGET	Cannabidiol 400	Hurd,Yasmin, Ph.D.	phase 2	cannabinoid receptor agonist	CB1 and CB2 receptors
THC/CBD	THC/CBD	Azienda Ospedaliera Universitaria Policlinico "G. Martino"	phase 3	cannabinoid	CB1 and CB2 receptors
medical cannabis	medical cannabis	HaEmek Medical Center, Israel	phase 3		CB1 and CB2 receptors
Single-dose of cannabis oil	Single-dose of cannabis oil	Hadassah Medical Organization	phase 3		CB1 and CB2 receptors
Dronabinol in Oral Dosage Form	Dronabinol in Oral Dosage Form	Arbeitsgemeinschaft medikamentoese Tumortherapie	phase 3	Cannabinoid receptor agonist	CB1 receptor, CB2 receptor
Dronabinol Capsules	Dronabinol Capsules	Montefiore Medical Center	phase 3	Cannabinoid receptor agonist	CB1 receptor, CB2 receptor
CimetrA-2	CimetrA-2	MGC Pharmaceuticals d.o.o	phase 3	cannabinoid receptor agonist	CB1/CB2 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cannabinoid receptor agonist class)

Hurd,Yasmin, Ph.D. · 1 drug in this class
MGC Pharmaceuticals d.o.o · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cannabidiol 400 — Competitive Intelligence Brief. https://druglandscape.com/ci/cannabidiol-400. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing